|
| Administration rule and mechanism of traditional Chinese medicine compound in the treatment of myasthenia gravis:a study based on data mining and network pharmacology |
| Hits 333 Download times 136 Received:August 28, 2023 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2024.03.18 |
| Key Words
data mining;network pharmacology;myasthenia gravis;medication rule;mechanism of action;traditional Chinese medicine |
| Author Name | Affiliation | E-mail | | ZHENG Hongming | The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000 China | | | HU Zhifan | The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000 China | | | HUANG Mengfen | The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000 China | | | CHEN Mingyu | The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000 China | | | LI Yiting | The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000 China | | | MIU Taosheng | The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000 China | | | MO Qiaolan | The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000 China | | | QIU Zexin | The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000 China | | | CHEN Bin | Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000 China | chenbin0576@vip.163.com |
|
| Abstract
|
| [Objective] To explore the medication rules of traditional Chinese medicine (TCM) compound in the treatment of myasthenia gravis(MG) based on the national patent,CNKI and Wangfang Database,and to analyze the mechanism of action of the core drug pair,in order to provide a theoretical basis for the treatment of MG with traditional Chinese medicine compound. [Methods] The prescription data of the treatment of myasthenia gravis by TCM compound were retrieved from National Intellectual Property Administration's China Patent Announcement database,CNKI and Wanfang database. Frequency statistics,association rule analysis and systematic cluster analysis were performed on the patented compound by R language,SPSS and IBM SPSS Modeler software and analyzed the medication rules of the patented TCM compound in the treatment of MG. Based on the network pharmacology method,the potential targets and pathways of the selected core drug pair were predicted,and the "Chinese medicine-component-target" and PPI interaction network were constructed. Autodock was used for molecular docking prediction. [Results] Data mining included 151 TCM compounds,352 Chinese herbs, including 26 high-frequency Chinese herbs. Association rule analysis screened out 76 core drug pairs,including 7 Chinese herbs. Cluster analysis obtained 7 categories,including 3 cluster prescriptions,3 cluster drug pairs and 1 single herbs. The core drug combinations of Chaihu,Angelica sinensis,Astragalus membranaceus,Codonopsis radix,Atractylodes atractylodes atractylodes and Cimichoma were selected for network pharmacology analysis,and 10 core active ingredients,including quercetin,luteolin,kaeferol,7-methoxy-2-methyl isoflavone,7-O-methylisobionsatin,isorhamnetin,formononetin,beta-sitosterol,Stigmasterol and Calycosin were obtained. And 14 core targets were obtained as well,including AKT1,EGFR,FOS,JUN,MYC,IL6,TNF,CASP3,IL1B,CRP,TP53,VEGFA,ESR1,and ERBB2. The results of molecular docking showed that the core components had stable binding with the core targets,and the average minimum binding energy was -6.23 kcal/mol. [Conclusion] This study revealed that the treatment of myasthenia gravis with traditional Chinese medicine compound is mainly based on the method of tonifying deficiency and loss,and supplemented with activating blood circulation and channeling channels,relaxing tendons and collaterals,and so on. The main active ingredients of the core drug combination "Radix Bupleuri,Angelicae Sinensis Radix,Hedysarum Multijugum Maxim,Codonopsis radix,Atractylodes Macrocephala Koidz and Cimicifugae Rhizoma" plays a therapeutic role in myasthenia gravis mainly by acting on cell components such as the postsynaptic membrane,affecting molecular functions such as G protein coupled acetylcholine receptor activity via participating in the regulation of immunity,inflammation and other mechanisms,and possibly targeting EGFR to treat thymus related myasthenia gravis,and it can provide a reference for the mechanism research and clinical medication of traditional Chinese medicine compound in treating myasthenia gravis. |
|
|
|
|
|
|
|
